Olaparib ( DrugBank: Olaparib )

2 diseases

ID	Disease name (Link within this page)	Number of trials
86	Pulmonary arterial hypertension	2
285	Fanconi anemia	2

86. Pulmonary arterial hypertension

Clinical trials : 1,181 / Drugs : 701 - (DrugBank : 126) / Drug target genes : 105 - Drug target pathways : 192

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03782818 (ClinicalTrials.gov)	November 20, 2019	17/12/2018	Olaparib for PAH: a Multicenter Clinical Trial	Olaparib for Pulmonary Arterial Hypertension: a Multicenter Clinical Trial	Pulmonary Arterial Hypertension	Drug: Olaparib	Laval University	Canadian Institutes of Health Research (CIHR);AstraZeneca	Recruiting	18 Years	75 Years	All	20	Phase 1/Phase 2	Canada
2	NCT03251872 (ClinicalTrials.gov)	October 25, 2018	13/8/2017	Olaparib for PAH: a Pilot Study	Olaparib for Pulmonary Arterial Hypertension: a Pilot Clinical Study	Pulmonary Arterial Hypertension	Drug: Olaparib	Laval University	NULL	Terminated	18 Years	75 Years	All	6	Early Phase 1	Canada

Clinical trials : 59 / Drugs : 118 - (DrugBank : 32) / Drug target genes : 31 - Drug target pathways : 155

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04483544 (ClinicalTrials.gov)	August 10, 2020	20/7/2020	Pembrolizumab and Olaparib in Cervical Cancer Patients	Immunotherapy in Combination With PARP Inhibition in Advanced Cervical Cancer Patients Functionally Competent or Deficient for the Fanconi Anemia Repair Pathway	Cervical Cancer;Cervical Carcinoma	Drug: pembrolizumab;Drug: olaparib	Baptist Health South Florida	Florida Department of Health;Merck Sharp & Dohme Corp.	Recruiting	18 Years	N/A	Female	48	Phase 2	United States
2	NCT04042831 (ClinicalTrials.gov)	June 9, 2020	29/7/2019	Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations	A Phase II Study of Olaparib in Patients With Advanced Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations	BRCA2 Gene Mutation;BRIP1 Gene Mutation;CHEK2 Gene Mutation;EMSY Gene Mutation;Fanconi Anemia Complementation Group Gene Mutation;Metastatic Bile Duct Carcinoma;MRE11 Gene Mutation;NBN Gene Mutation;PALB2 Gene Mutation;PTEN Gene Deletion;RAD51 Gene Mutation;ARID1A Gene Mutation;ATM Gene Mutation;ATR Gene Mutation;Bile Duct Adenocarcinoma;BRCA1 Gene Mutation	Drug: Olaparib	Academic and Community Cancer Research United	National Cancer Institute (NCI)	Recruiting	18 Years	N/A	All	36	Phase 2	United States